Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertriglyceridemia: HELP
Articles from Spain
Based on 149 articles published since 2008

These are the 149 published articles about Hypertriglyceridemia that originated from Spain during 2008-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6
1 Editorial [Hypertriglyceridemia and LMF 1: Another piece of the puzzle]. 2015

Valdivielso, Pedro. ·Unidad de Lípidos, Hospital Virgen de la Victoria,, Málaga, España; Departamento de Medicina y Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Universidad de Málaga, Málaga, España. Electronic address: valdivielso@uma.es. ·Clin Investig Arterioscler · Pubmed #26398545.

ABSTRACT: -- No abstract --

2 Review Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact. 2017

Guardiola, Montse / Ribalta, Josep. ·Unitat de Recerca en Lípids i Arteriosclerosi, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Sant Llorenç 21, 43201, Reus, Spain. · Unitat de Recerca en Lípids i Arteriosclerosi, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Sant Llorenç 21, 43201, Reus, Spain. josep.ribalta@urv.cat. ·Curr Atheroscler Rep · Pubmed #28500476.

ABSTRACT: PURPOSE OF REVIEW: This review is intended to summarize the genetic studies published during the last 3 years that help us understand the physiology of apoAV and its clinical implications. RECENT FINDINGS: APOA5 is probably the gene with the strongest effect on triglyceride (TG) metabolism. APOA5 is almost exclusively expressed in the liver, and its product apoAV has a very low circulating concentration. New physiological roles of apoAV have been recently elucidated, such as control of chylomicron production in the intestine and TG accumulation in adipose tissue. The key role of APOA5 in TG metabolism has been largely shown through genetic studies in association with either severe or moderate hypertriglyceridemia. Studies suggest that APOA5 variants affect not only total TG concentrations but also the entire lipoprotein subclass distribution, shifting them toward atherogenic dyslipidemia in high-risk subjects. Environmental interactions and epigenetic factors are also crucial in regulating these processes. Delineation of the mechanisms involved in the transcriptional control of the gene, combined with determination of biological significance of the SNPs in the APOA5 locus, would help to fully understand the effect of APOA5 on TGs. In summary, APOA5 variants cause hypertriglyceridemia. In high cardiovascular risk patients (e.g., patients with metabolic syndrome or type 2 diabetes), APOA5 variants elevate TG levels and shift the entire lipoprotein subclass distribution toward atherogenic dyslipidemia. At a physiological level, apoAV seems to encompass more roles than those initially suggested after its discovery.

3 Review The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview. 2015

Garcia-Cazorla, Àngels / Mochel, Fanny / Lamari, Foudil / Saudubray, Jean-Marie. ·Department of Neurology, Neurometabolic Unit, Hospital Sant Joan de Déu and CIBERER, ISCIII, Barcelona, Spain, agarcia@hsjdbcn.org. ·J Inherit Metab Dis · Pubmed #25413954.

ABSTRACT: Over one hundred diseases related to inherited defects of complex lipids synthesis and remodeling are now reported. Most of them were described within the last 5 years. New descriptions and phenotypes are expanding rapidly. While the associated clinical phenotype is currently difficult to outline, with only a few patients identified, it appears that all organs and systems may be affected. The main clinical presentations can be divided into (1) Diseases affecting the central and peripheral nervous system. Complex lipid synthesis disorders produce prominent motor manifestations due to upper and/or lower motoneuron degeneration. Motor signs are often complex, associated with other neurological and extra-neurological signs. Three neurological phenotypes, spastic paraparesis, neurodegeneration with brain iron accumulation and peripheral neuropathies, deserve special attention. Many apparently well clinically defined syndromes are not distinct entities, but rather clusters on a continuous spectrum, like for the PNPLA6-associated diseases, extending from Boucher-Neuhauser syndrome via Gordon Holmes syndrome to spastic ataxia and pure hereditary spastic paraplegia; (2) Muscular/cardiac presentations; (3) Skin symptoms mostly represented by syndromic (neurocutaneous) and non syndromic ichthyosis; (4) Retinal dystrophies with syndromic and non syndromic retinitis pigmentosa, Leber congenital amaurosis, cone rod dystrophy, Stargardt disease; (5) Congenital bone dysplasia and segmental overgrowth disorders with congenital lipomatosis; (6) Liver presentations characterized mainly by transient neonatal cholestatic jaundice and non alcoholic liver steatosis with hypertriglyceridemia; and (7) Renal and immune presentations. Lipidomics and molecular functional studies could help to elucidate the mechanism(s) of dominant versus recessive inheritance observed for the same gene in a growing number of these disorders.

4 Review Current knowledge of hypertriglyceridemic pancreatitis. 2014

Valdivielso, Pedro / Ramírez-Bueno, Alba / Ewald, Nils. ·Department of Medicine and Dermatology, University of Malaga, Spain; Servicio de Medicina Interna, Hospital Virgen de la Victoria, Malaga, Spain. · Servicio de Medicina Interna, Hospital Virgen de la Victoria, Malaga, Spain. · Justus-Liebig-University Giessen, 35392 Giessen, Germany; General Hospital Luebbecke-Rahden, Department of Internal Medicine, 32312 Luebbecke, Germany. Electronic address: nils.ewald@innere.med.uni-giessen.de. ·Eur J Intern Med · Pubmed #25269432.

ABSTRACT: Severe hypertriglyceridemia (HTG) is a well established and the most common cause of acute pancreatitis (AP) after alcohol and gall stone disease. It is alleged to account for up to 10% of all pancreatitis episodes. Studies suggest that in patients with triglyceride (TG) levels>1000 mg/dL (>11.3 mmol/L), hypertriglyceridemia-induced acute pancreatitis (HTGP-AP) occurs in approximately 15-20% of all subjects referred to Lipid Clinics. Until now, there is no clear evidence which patients with severe HTG will develop pancreatitis and which will not. Underlying pathophysiological concepts include hydrolysis of TG by pancreatic lipase and excessive formation of free fatty acids with inflammatory changes and capillary injury. Additionally hyperviscosity and ischemia may play a decisive role. The clinical features of HTG-AP patients are supposed to be no different from patients with AP of other etiologies. Yet, there are well-conducted studies suggesting that HTG-AP is associated with a higher severity and complication rate. Therapeutic measurements in HTG-AP include dietary modifications, different antihyperlipidemic agents, insulin and/or heparin treatment. The beneficial use of plasmapheresis is repeatedly reported and suggested in many studies. Yet, due to the lack of randomized and controlled trials, it is currently unknown if plasmapheresis may improve morbidity and mortality in the clinical setting of HTG-AP. Since there are no commonly accepted clinical guidelines in the management of HTG-AP, there is a definite need for an international, multicenter approach to this important subject.

5 Review The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. 2014

Hegele, Robert A / Ginsberg, Henry N / Chapman, M John / Nordestgaard, Børge G / Kuivenhoven, Jan Albert / Averna, Maurizio / Borén, Jan / Bruckert, Eric / Catapano, Alberico L / Descamps, Olivier S / Hovingh, G Kees / Humphries, Steve E / Kovanen, Petri T / Masana, Luis / Pajukanta, Päivi / Parhofer, Klaus G / Raal, Frederick J / Ray, Kausik K / Santos, Raul D / Stalenhoef, Anton F H / Stroes, Erik / Taskinen, Marja-Riitta / Tybjærg-Hansen, Anne / Watts, Gerald F / Wiklund, Olov / Anonymous2400791. ·Department of Medicine, Western University, London, ON, Canada. Electronic address: hegele@robarts.ca. · Irving Institute for Clinical and Translational Research, Columbia University, New York, NY, USA. · Dyslipidaemia and Atherosclerosis Research Unit, INSERM U939, Pitié-Salpêtrière University Hospital, Paris, France. · Department of Diagnostic Sciences, Herlev Hospital, University of Copenhagen, Denmark. · Department of Molecular Genetics, University Medical Center Groningen, University of Groningen, Netherlands. · Department of Internal Medicine, University of Palermo, Palermo, Italy. · Strategic Research Center, Sahlgrenska Center for Cardiovascular and Metabolic Research, University of Gothenburg, Gothenburg, Sweden. · Department of Endocrinology and Metabolism, Endocrinology and Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris, France. · Department of Pharmacological Sciences, University of Milan and Multimedica IRCSS, Milan, Italy. · Centre de Recherche Médicale, Lipid Clinic, Hopital de Jolimont, Haine Saint-Paul, Belgium. · Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. · Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK. · Wihuri Research Institute, Helsinki, Finland. · Vascular Medicine and Metabolism Unit, Sant Joan University Hospital, Universitat Rovira & Virgili, IISPV, CIBERDEM, Reus, Spain. · Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. · Department of Endocrinology and Metabolism, University of Munich, Munich, Germany. · Division of Endocrinology and Metabolism, Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa. · Cardiovascular Sciences Research Centre, St George's Hospital NHS Trust, London, UK. · Lipid Clinic Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil. · Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands. · Cardiovascular Research Group, Heart and Lung Centre, Helsinki University Central Hospital and Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. · Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. · School of Medicine and Pharmacology, Royal Perth Hospital Unit, The University of Western Australia, Perth, WA, Australia. · Department of Cardiology, Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden. ·Lancet Diabetes Endocrinol · Pubmed #24731657.

ABSTRACT: Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a monogenic cause; and mild-to-moderate (triglyceride concentration 2-10 mmol/L). Because of clustering of susceptibility alleles and secondary factors in families, biochemical screening and counselling for family members is essential, but routine genetic testing is not warranted. Treatment includes management of lifestyle and secondary factors, and pharmacotherapy. In severe hypertriglyceridaemia, intervention is indicated because of pancreatitis risk; in mild-to-moderate hypertriglyceridaemia, intervention can be indicated to prevent cardiovascular disease, dependent on triglyceride concentration, concomitant lipoprotein disturbances, and overall cardiovascular risk.

6 Review [Acute hypertrygliceridemic pancreatitis]. 2013

Senosiain Lalastra, Carla / Tavío Hernández, Eduardo / Moreira Vicente, Victor / Maroto Castellanos, Maite / García Sánchez, Maria Concepción / Aicart Ramos, Marta / Téllez Vivajos, Luis / Cuño Roldán, José Luis. ·Servicio de Gastroenterología, Hospital Universitario Ramón y Cajal, Madrid, España. carsenosiain@gmail.com ·Gastroenterol Hepatol · Pubmed #23522394.

ABSTRACT: Acute hypertriglyceridemic pancreatitis is the third cause of acute pancreatitis in the Western population. There is usually an underlying alteration in lipid metabolism and a secondary factor. Clinical presentation is similar to that of pancreatitis of other etiologies, but the course of acute hypertriglyceridemic pancreatitis seems to be worse and more recurrent. Some laboratory data can be artefacts, leading to diagnostic errors. This is the case of amylase, which can show false low levels. Treatment is based on intense fluidotherapy and analgesia. When there is no response to conservative management, other methods to lower triglyceride levels should be used. Several options are available, such as plasmapheresis, insulin, and heparin. The present article provides a review of the current literature on this entity.

7 Review [Fospropofol: A new prodrug of propofol]. 2012

Telletxea, S / Lauzirika, Z / Etxebarria, A / Ortega, L F. ·Servicio de Anestesiología, Reanimación y Terapia del Dolor, Hospital de Galdakao, Bizkaia, España. sorkunde.telletxeabenguria@osakidetza.net ·Rev Esp Anestesiol Reanim · Pubmed #22748853.

ABSTRACT: The development of new propofol formulations has advanced rapidly in the last ten years with the achievement of the marketing a new prodrug of propofol: fospropofol, pharmacologically different from the original compound. It is a water soluble compound that requires metabolism of the prodrug to propofol, which leads to a time delay between its administration and the appearance of its pharmacological effect. Its pharmacokinetic and pharmacodynamic characteristics are different to the original formula. Due to its formulation it does not cause pain on intravenous injection, does not lead to hyperlipidaemia or excess bacterial growth. Although it is currently unavailable in Spain, it has been approved by the FDA (American Food and Drug Administration) for sedation in controlled care in diagnostic and therapeutic procedures in adults. It must only be administered by personnel qualified to administer anaesthesia, and the patients must be monitored throughout the whole procedure.

8 Review Nutrigenetics of the postprandial lipoprotein metabolism: evidences from human intervention studies. 2011

Perez-Martinez, Pablo / Garcia-Rios, Antonio / Delgado-Lista, Javier / Perez-Jimenez, Francisco / Lopez-Miranda, Jose. ·Lipids and Atherosclerosis Research Unit, Reina Sofia University Hospital. Avda. Menéndez Pidal, s/n, 14004 Cordoba, Spain. pablopermar@yahoo.es ·Curr Vasc Pharmacol · Pubmed #21314629.

ABSTRACT: Accumulating evidence suggests that elevated plasma triglycerides concentrations, in both the fasting and the postprandial states, may pose a significant independent risk for cardiovascular disease (CVD). Both fasting and postprandial lipoprotein concentrations vary substantially among individuals, and this inter individual variability is driven by a combination of non-genetic and genetic factors. Regarding the genetic component, the efforts to elucidate the variability in postprandial response have resulted in the identification of associations with multiple lipid candidate genes. However, most reported associations are based on very simple models including one single-nucleotide polymorphism (SNP) or haplotype at a time and small sample sizes. Progress in this promising area of research requires more comprehensive experimental models, including larger sample sizes that will allow investigating gene-gene interactions. Reviews of the literature in the area of ApoA5, GCKR, and PLIN genes and postprandial lipemia are used to demonstrate the complexities of genotype-phenotype associations. Knowledge of how these and other genes influence postprandial response should increase the understanding of personalised nutrition.

9 Review [Fatty liver and its clinical management in obese adolescents]. 2011

González Jiménez, Emilio / Schmidt Río-Valle, Jacqueline / Álvarez Ferre, Judit. ·Departamento de Enfermería, Facultad de Ciencias de la Salud, Universidad de Granada, Granada, España. emigoji@ugr.es ·Endocrinol Nutr · Pubmed #21216209.

ABSTRACT: Liver steatosis, also called non-alcoholic fatty liver, is characterized by a pathological fat accumulation in the liver, leading to liver damage in the form of inflammation and fibrosis. These histological features are similar to those in alcoholic hepatitis. Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk. The aim of this study was to provide an update on the concepts, pathophysiology and clinical management of hepatic steatosis secondary to obesity at an early age.

10 Review [Impact of apolipoprotein A5 on cardiovascular risk. Genetic and environmental modulation]. 2010

Sotos-Prieto, Mercedes / Francés, Francesc / Corella, Dolores. ·Departamento de Medicina Preventiva y Salud Pública, Ciencidas de la Alimentación, Toxicología y Medicina Legal, Universitat de València y CIBER Fisiopatologla de la Obesidad y Nutrición, Instituto de Salud Carlos III. Mercedes.Sotos@uv.es ·Rev Med Chil · Pubmed #21043084.

ABSTRACT: Triglyceride concentrations are an independent risk factor for coronary heart disease. Apolipoprotein A5 gene (APOAS) has an important role determining triglyceride metabolism and it is a potential cardiovascular risk. However the mechanisms for these actions are not well-known. Despite the different allelic frequency of its major polymorphisms in different populations, multiple studies have shown consistent associations between these variants and fasting triglycerides. Variations in the APOA5 gene have also been associated with postprandial triglycerides, as well as with different sizes of lipoproteins and other markers. Moreover, some of the APOA5 gene variants have been associated with ischemic heart disease, stroke, and carotid intima media thickness, although the references on this issue are scanty and contradictory. This may be due to the presence of gene-environment interactions that have been poorly studied until now. Among the few studies that have examined the influence of environmental factors on possible genetic variations, the most important are those that contemplate possible gene-diet interactions. However, the evidence is still scarce and more research is required in the field of nutrigenomics. To understand the impact of this gene on cardiovascular disease, we review the genetic functionality and variability of APOA5, its associations with intermediate and final phenotypes and gene-environment interactions detected.

11 Review Disturbances in lipid metabolism in diabetic pregnancy - Are these the cause of the problem? 2010

Herrera, Emilio / Ortega-Senovilla, Henar. ·Universidad San Pablo CEU, Boadilla del Monte, Madrid, Spain. eherrera@ceu.es ·Best Pract Res Clin Endocrinol Metab · Pubmed #20832733.

ABSTRACT: The most common neonatal complication of gestational diabetes (GDM) is macrosomia. During early pregnancy an accumulation of maternal fat depots occurs followed by increased adipose tissue lipolysis and subsequent hyperlipidaemia, which mainly corresponds to increased triglycerides (TG) in all circulating lipoproteins. In GDM women, the enhanced insulin resistance and decreased oestrogens are responsible for the reported wide range of dyslipidaemic conditions. In GDM, decreased proportion of long chain polyunsaturated fatty acids in fetus plasma could result from decreased supply, impaired placental transfer or even altered intrauterine metabolism. A positive correlation between maternal TG and neonatal body weight or fat mass has been found in GDM. Augmented oxidative stress and altered adipokines have also been found, with an adverse outcome even in normoglycaemic conditions. Thus, although additional studies are required, overall these findings indicate that altered maternal lipid metabolism rather than hyperglycaemia constitutes a risk for macrosomia in GDM.

12 Review Advances in the medical treatment of diabetic retinopathy. 2009

Simó, Rafael / Hernández, Cristina. ·CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. rsimo@ir.vhebron.net ·Diabetes Care · Pubmed #19638526.

ABSTRACT: -- No abstract --

13 Clinical Trial Association between Eating Speed and Classical Cardiovascular Risk Factors: A Cross-Sectional Study. 2019

Paz-Graniel, Indira / Babio, Nancy / Mendez, Ignacio / Salas-Salvadó, Jordi. ·Department of Biochemistry and Biotechnology, Human Nutrition Unit, Universitat Rovira i Virgili, Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital Universitati Sant Joan de Reus, Reus 43201, Spain. nut.indirapaz@gmail.com. · Department of Biochemistry and Biotechnology, Human Nutrition Unit, Universitat Rovira i Virgili, Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital Universitati Sant Joan de Reus, Reus 43201, Spain. nancy.babio@urv.cat. · Consorcio CIBER, M.P. (CIBEROBN), Fisiopatología de la Obesidad y la Nutrición, Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain. nancy.babio@urv.cat. · Department of Biochemistry and Biotechnology, Human Nutrition Unit, Universitat Rovira i Virgili, Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital Universitati Sant Joan de Reus, Reus 43201, Spain. ignacioagustinmg@gmail.com. · Department of Biochemistry and Biotechnology, Human Nutrition Unit, Universitat Rovira i Virgili, Institut d'Investigació Sanitària Pere i Virgili (IISPV), Hospital Universitati Sant Joan de Reus, Reus 43201, Spain. jordi.salas@urv.cat. · Consorcio CIBER, M.P. (CIBEROBN), Fisiopatología de la Obesidad y la Nutrición, Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain. jordi.salas@urv.cat. ·Nutrients · Pubmed #30621124.

ABSTRACT: Cardiovascular disease (CVD) is one of the main causes of morbidity and mortality around the world. Lifestyle is recognized as a key factor in the development of metabolic disorders and CVD. Recently, eating speed has been of particular interest since some studies have associated it with the development of obesity and other cardiometabolic disorders. We aimed to assess the association between eating speed and various cardiovascular risk factors. We conducted a cross-sectional analysis within the framework of the PREDIMED (Prevención con Dieta Mediterránea) study with 792 participants from the Reus-Tarragona center. Eating speed was self-reported according to participant perception and categorized as slow, medium, or fast. The association between eating speed and cardiovascular risk factors was assessed using Cox regression models with constant time of follow-up for all individuals. Compared to participants in the slow eating speed category, those in the faster eating speed category were 59% more likely to have the hypertriglyceridemia component of the metabolic syndrome (MetS) (Hazard Ratio, (HR) 1.59; 95% Confidence Interval (CI) 1.16⁻2.17), even after adjustment for potential confounders (HR 1.47; 95% CI 1.08⁻2.02). No other significant differences were observed. Eating speed was positively associated with the prevalence of the hypertriglyceridemia component of the MetS in a senior population at high cardiovascular risk.

14 Clinical Trial Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. 2017

Müller-Wieland, Dirk / Leiter, Lawrence A / Cariou, Bertrand / Letierce, Alexia / Colhoun, Helen M / Del Prato, Stefano / Henry, Robert R / Tinahones, Francisco J / Aurand, Lisa / Maroni, Jaman / Ray, Kausik K / Bujas-Bobanovic, Maja. ·Department of Internal Medicine I, University Hospital Aachen, Pauwelsstr. 30, 52074, Aachen, Germany. dirmueller@ukaachen.de. · Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. · Institut du Thorax, CHU Nantes, Nantes, France. · Biostatistics and Programming Department, Sanofi, Chilly-Mazarin, France. · University of Edinburgh, Edinburgh, Scotland, UK. · Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. · University of California San Diego School of Medicine, Center for Metabolic Research, Veterans Affairs, San Diego Healthcare System, San Diego, CA, USA. · CIBERobn, Hospital Virgen de la Victoria, Málaga University, Málaga, Spain. · Sanofi, Bridgewater, NJ, USA. · Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA. · Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK. · Sanofi, Paris, France. ·Cardiovasc Diabetol · Pubmed #28545518.

ABSTRACT: BACKGROUND: Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more closely align with cardiovascular risk than low-density lipoprotein cholesterol (LDL-C). We describe the design and rationale of the ODYSSEY DM-DYSLIPIDEMIA study that assesses the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, versus lipid-lowering usual care in individuals with T2DM and mixed dyslipidaemia at high cardiovascular risk with non-HDL-C inadequately controlled despite maximally tolerated statin therapy. For the first time, atherogenic cholesterol-lowering with a PCSK9 inhibitor will be assessed with non-HDL-C as the primary endpoint with usual care as the comparator. METHODS: DM-DYSLIPIDEMIA is a Phase 3b/4, randomised, open-label, parallel group, multinational study that planned to enrol 420 individuals. Main inclusion criteria were T2DM and mixed dyslipidaemia (non-HDL-C ≥100 mg/dl [≥2.59 mmol/l], and triglycerides ≥150 and <500 mg/dl [≥1.70 and <5.65 mmol/l]) with documented atherosclerotic cardiovascular disease or ≥1 additional cardiovascular risk factor. Participants were randomised (2:1) to alirocumab 75 mg every 2 weeks (Q2W) or lipid-lowering usual care on top of maximally tolerated statin (or no statin if intolerant). If randomised to usual care, investigators were able to add their pre-specified choice of one of the following to the patient's current statin regimen: ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid, in accordance with local standard-of-care. Alirocumab-treated individuals with non-HDL-C ≥100 mg/dl at week 8 will undergo a blinded dose increase to 150 mg Q2W at week 12. The primary efficacy endpoint is non-HDL-C change from baseline to week 24 with alirocumab versus usual care; other lipid levels (including LDL-C), glycaemia-related measures, safety and tolerability will also be assessed. Alirocumab will be compared to fenofibrate in a secondary analysis. RESULTS: Recruitment completed with 413 individuals randomised in 14 countries worldwide. Results of this trial are expected in the second quarter of 2017. CONCLUSIONS: ODYSSEY DM-DYSLIPIDEMIA will provide information on the efficacy and safety of alirocumab versus lipid-lowering usual care in individuals with T2DM and mixed dyslipidaemia at high cardiovascular risk using non-HDL-C as the primary efficacy endpoint. Trial registration NCT02642159 (registered December 24, 2015).


Blumenfeld Olivares, Javier Andrés / San Mauro Martín, Ismael / Calle, Maria Elisa / Bischofberger Valdés, Cornelia / Perez Arruche, Eva / Arce Delgado, Esperanza / Ciudad, María Jose / Hernández Cabría, Marta / Collado Yurita, Luis. ·Hospital Universitario El Escorial, San Lorenzo de El Escorial.. javierandres.blumenfeld@salud.madrid.org. · Facultad de Medicina, Universidad Complutense de Madrid.. javierandres.blumenfeld@salud.madrid.org. · Departamento de Nutrición, Corporación Alimentaria Peñasanta, España.. javierandres.blumenfeld@salud.madrid.org. ·Nutr Hosp · Pubmed #26319820.

ABSTRACT: INTRODUCTION: in the last few years, as the rate of childhood obesity has been rising, there has been a parallel increase in the incidence of dislipemia in the pediatric population, in which blood triglycerids might play an important role. Plant sterols have been shown to be useful in the tratment of hypercholesterolemia, but not of hypertrygliceridemia. Our study focusses on determining the efficacy of phytosterol-supplemented milk for the treatment of hypertriglyceridemia in children. Study Population and Method: we designed a double- blind, randomized, controlled clinical trial on 67 pediatric patients. The treatment group received low-fat, phytosterol-supplemented milk and the control group received low-fat conventional milk. RESULTS: we observed differences in triglyceridemia between the phytosterol-supplemented group and the non-supplemented group. The effect attributable to the intake of milk supplemented with plant sterols was a reduction of triglyceridemia of 5.88 mg/dl compared with the control group. CONCLUSION: we conclude that phytosterol-supplemented milk (2.24 gr of plant sterols daily) might be an adequate tool in the management of hypertriglyceridemia in pediatric patients.

16 Clinical Trial [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex]. 2014

Mateos-González, M Elena / López-Laso, Eduardo / Vicente-Rueda, Josefina / Camino-León, Rafael / Fernández-Ramos, Joaquín A / Baena-Gómez, M Auxiliadora / Peña-Rosa, M José. ·Hospital Universitario Reina Sofia. IMIBIC. CIBERER-ISCIII. , Cordoba, Espana. ·Rev Neurol · Pubmed #25418144.

ABSTRACT: INTRODUCTION: Subependymal giant cell astrocytomas (SEGA) appear in 5-20% of patients with tuberous sclerosis complex (TSC) and are the most common brain tumours in TSC. They are benign tumours, of a glioneural stock, that develop mainly in the first two decades of life, generally close to the foramen of Monro, and can trigger hydrocephalus and intracranial hypertension. It is one of the leading causes of death in TSC. Recently mTOR inhibitors have proved to be a therapeutic alternative to surgical excision. AIM. To describe our experience of using everolimus to treat patients with SEGA and TSC. PATIENTS AND METHODS: We conducted a prospective study of the responses of patients with TSC and at least one SEGA undergoing growth. RESULTS: Three females and three males with a mean age of 12.3 years received treatment. One patient had previously undergone surgery due to SEGA with hydrocephalus. The maximum mean diameter of the SEGA on beginning treatment was 15.3 mm (range: 11.3-24.8 mm). Treatment was established with everolimus, 2.5 mg/day administered orally in patients with a body surface area < 1.2 m2, and 5 mg/day in patients with a body surface area > 1.2 m2. Two patients presented hypertriglyceridemia; one, anorexia; another, a mouth ulcer; and one, amenorrhoea. The mean reduction in the volume of the SEGA at three months of treatment was 46%, and the reduction remained steady in later control examinations (6-25 months). CONCLUSIONS: Treatment with everolimus reduces the size of SEGA associated with TSC with an adequate safety profile, and constitutes an alternative to surgery in certain cases.

17 Clinical Trial Composition of two Spanish common dry beans (Phaseolus vulgaris), 'Almonga' and 'Curruquilla', and their postprandial effect in type 2 diabetics. 2013

Olmedilla-Alonso, Begoña / Pedrosa, Mercedes Martín / Cuadrado, Carmen / Brito, Miguel / Asensio-S-Manzanera, Carmen / Asensio-Vegas, Carmen. ·Departamento Metabolismo y Nutrición, Instituto de Ciencia y Tecnología de Alimentos y Nutrición (ICTAN)-CSIC, 28040 Madrid, Spain. Bolmedilla@ictan.csic.es ·J Sci Food Agric · Pubmed #22936114.

ABSTRACT: BACKGROUND: Legume consumption has been associated with a lower risk of developing type 2 diabetes. However, the type of legume is a modifier of its effect. Two Spanish dry bean varieties-white ('Almonga') and cream ('Curruquilla')-were analyzed and used in a postprandial study in type 2 diabetics to assess glucose, insulin and triacylglycerol in blood. RESULTS: 'Curruquilla' variety had higher total galactoside (stachyose, mainly), trypsin inhibitors and lectin content than 'Almonga'. The canning liquid was discarded prior to the analysis and the bean consumption by the subjects. The canning process reduced the total α-galactoside content (>50%), practically eliminated trypsin inhibitors, and no lectin content was found. After bean consumption, maximum glucose was obtained at 60 min and was three times lower than that in bread. After bean intake, maximum insulin was produced 60 min with 'Almonga' and occurred later (90 min) with 'Curruquilla' and bread. After 'Almonga' intake, the area under the curve response of triglycerides was 14% lower compared to bread (P = 0.013). CONCLUSIONS: 'Almonga' and 'Curruquilla' are similar in the content of the nutritional but not in that of the antinutritional components. Both beans showed similar effects on blood glucose and insulin in type 2 diabetics and marked differences compared to those of bread in terms of magnitude and time course, but only 'Almonga' rendered a significant reduction in the triglyceridemic response.

18 Clinical Trial Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. 2012

Clemente-Postigo, M / Queipo-Ortuño, M I / Murri, M / Boto-Ordoñez, M / Perez-Martinez, P / Andres-Lacueva, C / Cardona, F / Tinahones, F J. ·Laboratorio de Investigación Biomédica, Hospital Universitario Virgen de la Victoria, Spain. ·J Lipid Res · Pubmed #22394503.

ABSTRACT: The low-grade inflammation observed in obesity has been associated with a high-fat diet, though this relation is not fully understood. Bacterial endotoxin, produced by gut microbiota, may be the linking factor. However, this has not been confirmed in obese patients. To study the relationship between a high-fat diet and bacterial endotoxin, we analyzed postprandial endotoxemia in morbidly obese patients after a fat overload. The endotoxin levels were determined in serum and the chylomicron fraction at baseline and 3 h after a fat overload in 40 morbidly obese patients and their levels related with the degree of insulin resistance and postprandial hypertriglyceridemia. The morbidly obese patients with the highest postprandial hypertriglyceridemia showed a significant increase in lipopolysaccharide (LPS) levels in serum and the chylomicron fraction after the fat overload. Postprandial chylomicron LPS levels correlated positively with the difference between postprandial triglycerides and baseline triglycerides. There were no significant correlations between C-reactive protein (CRP) and LPS levels. The main variables contributing to serum LPS levels after fat overload were baseline and postprandial triglyceride levels but not glucose or insulin resistance. Additionally, superoxide dismutase activity decreased significantly after the fat overload. Postprandial LPS increase after a fat overload is related to postprandial hypertriglyceridemia but not to degree of insulin resistance in morbidly obese patients.

19 Clinical Trial A high-fat meal promotes lipid-load and apolipoprotein B-48 receptor transcriptional activity in circulating monocytes. 2011

Varela, Lourdes M / Ortega, Almudena / Bermudez, Beatriz / Lopez, Sergio / Pacheco, Yolanda M / Villar, Jose / Abia, Rocio / Muriana, Francisco J G. ·Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, Seville, Spain. ·Am J Clin Nutr · Pubmed #21367954.

ABSTRACT: BACKGROUND: The postprandial metabolism of dietary fats results in the production of apolipoprotein B-48 (apoB48)-containing triglyceride-rich lipoproteins (TRLs), which cause rapid receptor-mediated macrophage lipid engorgement via the apoB48 cell surface receptor (apoB48R). Monocytes circulate together with apoB48-containing TRLs in the postprandial bloodstream and may start accumulating lipids even before their migration to tissues and differentiation to macrophages. OBJECTIVE: We sought to determine whether circulating monocytes are equipped with apoB48R and whether, in the postprandial state, circulating monocytes accumulate lipids and modulate apoB48R transcriptional activity after intake of a high-fat meal. DESIGN: In a crossover design, we studied the effect of a high-fat meal on fasting and postprandial concentrations of triglycerides, free fatty acids, cholesterol, and insulin in 12 healthy men. TRLs and monocytes were freshly isolated at fasting, hourly until the postprandial peak, and at the late postprandial phase. TRLs were subjected to triglycerides, apoB48, and apolipoprotein B-100 analyses; and lipid accumulation and apoB48R mRNA expression levels were measured in monocytes. RESULTS: Monocytes showed a time-dependent lipid accumulation in response to the high-fat meal, which was paralleled by an increase in apoB48R mRNA expression levels. These effects were coincident only with an increase in apoB48-containing TRLs in the postprandial phase and were also observed ex vivo in freshly isolated monocytes incubated with apoB48-containing TRLs. CONCLUSION: In a setting of abundant plasma apoB48-containing TRLs, these findings highlight the role of dietary fat in inducing lipid accumulation and apoB48R gene transcription in circulating monocytes.

20 Clinical Trial Effects of meals rich in either monounsaturated or saturated fat on lipid concentrations and on insulin secretion and action in subjects with high fasting triglyceride concentrations. 2011

Lopez, Sergio / Bermudez, Beatriz / Ortega, Almudena / Varela, Lourdes M / Pacheco, Yolanda M / Villar, Jose / Abia, Rocio / Muriana, Francisco J G. ·Laboratory of Cellular and Molecular Nutrition, Instituto de la Grasa, Seville, Spain. ·Am J Clin Nutr · Pubmed #21209225.

ABSTRACT: BACKGROUND: The nature of dietary fats and fasting concentrations of triglycerides affect postprandial hypertriglyceridemia and glucose homeostasis. OBJECTIVES: The objectives were to examine the effects of meals enriched in monounsaturated fatty acids (MUFAs) or saturated fatty acids (SFAs) on postprandial lipid, glucose, and insulin concentrations and to examine the extent of β cell function and insulin sensitivity in subjects with high fasting triglyceride concentrations. DESIGN: Fourteen men with fasting hypertriglyceridemia and normal glucose tolerance were given meals (≈10 kcal/kg body weight) containing MUFAs, SFAs, or no fat. Blood samples were collected at baseline and hourly over 8 h for analysis. RESULTS: The high-fat meals significantly increased postprandial concentrations of triglycerides, nonesterified fatty acids, and insulin and postprandial indexes of β cell function. However, postprandial indexes of insulin sensitivity decreased significantly. These effects were significantly attenuated with MUFAs relative to SFAs. CONCLUSIONS: MUFAs postprandially buffered β cell hyperactivity and insulin intolerance relative to SFAs in subjects with high fasting triglyceride concentrations. These data suggest that, in contrast with SFAs, MUFA-based strategies may provide cardiovascular benefits to persons at risk by limiting lipid and insulin excursions and may contribute to optimal glycemic control after meal challenges.

21 Clinical Trial Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study. 2009

De Luis, D A / Conde, R / Aller, R / Izaola, O / González Sagrado, M / Perez Castrillón, J L / Dueñas, A / Romero, E. ·Institute of Endocrinology and Nutrition, Medicine School and Hospital Rio Hortega, University of Valladolid, Valladolid, Spain. dadluis@yahoo.es ·Eur Rev Med Pharmacol Sci · Pubmed #19364085.

ABSTRACT: BACKGROUND AND OBJECTIVES: Epidemiological and interventional studies suggest that a high dietary intake of n-3 polyunsaturated fatty acids may confer a protective effect against atherosclerotic disease and reduce serum triglycerides levels. The aim of our study was to investigate the effectivity on triglyceride levels and inflammatory markers of a concentrated of n-3 fatty acids in patients with type 2 diabetes mellitus and hypertriglyceridaemia. SUBJECTS: A total of 30 patients (16 males and 14 females) with diabetes mellitus type 2 and hypertriglyceridemia (> 200 mg/dl) were included in the study. Patients received two capsules of eicosapentaenoic 465 mg and docosahexanoic 375 mg daily for 12 weeks. RESULTS: Triglycerides levels and non HDL-cholesterol decreased (326 +/- 113.5 vs. 216.4 +/- 57 mg/dl; p < 0.05) and (103.87 +/- 44 vs. 89.6 +/- 14 mg/dl; p < 0.05), respectively. HDL-cholesterol levels increased (39.6 +/- 10.7 vs. 46.4 +/- 8.7 mg/dl; p < 0.05). C reactive protein decreased (5.98 +/- 3.9 vs. 3.9 +/- 1.6 mg/dl; p < 0.05) and TNF-alpha levels decreased (16.24 +/- 5.5 vs. 13.3 +/- 5.8 pg/dl; p < 0.05), without significant changes in IL-6 levels. In conclusion, an n-3 polyunsaturated intervention improved lipid profile and inflammatory markers in patients with diabetes mellitus type 2 and hypertriglyceridaemia.

22 Clinical Trial Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. 2009

Pérez-Elias, M Jesús / Sánchez-Conde, María / Soriano, Vicente / Mallolas, Josep / Luque, Isabel / Rodríguez-Alcántara, Felipe / Anonymous230622. ·Hospital Ramon y Cajal, Madrid, Spain. ·Enferm Infecc Microbiol Clin · Pubmed #19218000.

ABSTRACT: INTRODUCTION: The use of protease inhibitors (PI) has led to a decrease in HIV-1-related mortality and morbidity. The objective of this study was to collect safety data on treatment with fosamprenavir/ritonavir (FPV/r) 700/100mg BID in HIV-infected patients through an expanded access program. PATIENTS AND METHODS: Prospective, multicenter, noncomparative study in HIV-1 infected adults, for whom a regimen containing FPV/r 700/100mg BID was appropriate. RESULTS: A total of 678 patients were included in the intention-to-treat (ITT) and safety population. The on-treatment (OT) population contained 587 patients: 76% male, 98% Caucasian, and median age 41 years. Median CD4 cell count was 351 cells/microL, HIV-RNA was 3 log copies/mL, and 49% of patients were in CDC class C. After 24 weeks of treatment, serum viral load decreased a median of 1.3 log copies/mL and 73% of patients had <400 copies/mL (P<.0001 vs. baseline); 48-week results were similar. CD4 cell count increased a median of 49 and 62 cells/microL at 24 and 48 weeks, respectively. Adverse events (AEs) associated with the study medication occurred in 21% of patients. CONCLUSIONS: Ritonavir-boosted fosamprenavir as part of antiretroviral therapy is a potent, safe treatment in real-life clinical circumstances.

23 Clinical Trial First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. 2008

Domingo, Pere / Suárez-Lozano, Ignacio / Torres, Ferran / Teira, Ramón / Lopez-Aldeguer, José / Vidal, Francesc / Muñoz, Agustín / Viciana, Pompeyo / Lozano, Fernando / Vergara, Antonio / Roca, Bernadino / García Alcalde, Ma Luisa / Cosín, Jaime / Terrón, Alberto / Galindo, Ma José / Geijo, Paloma / Ribera, Esteban / Gonzalez, Juan / Sanchez, Trinitario / Lacalle, Juan Ramón / Garrido, Myriam. ·Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08025 Barcelona, Spain. pdomingo@santpau.es ·J Antimicrob Chemother · Pubmed #18356150.

ABSTRACT: BACKGROUND: Efavirenz and lopinavir/ritonavir are both recommended antiretroviral agents for combination first-line therapy, although information on direct comparisons between them is scarce. A retrospective longitudinal study from the VACH cohort comparing both regimens was performed. METHODS: Efficacy was examined comparing time to virological failure, CD4 recovery and clinical progression. Tolerability was examined comparing time to treatment discontinuation for any reason and for toxicity. Survival analysis was conducted using the Kaplan-Meier method, and standard and weighted Cox regression models. RESULTS: A total of 1550 antiretroviral-naive patients starting a two-nucleoside reverse transcriptase inhibitor regimen plus either efavirenz (n = 1159) or lopinavir/ritonavir (n = 391) were included in the study. At baseline, patients starting lopinavir/ritonavir had higher HIV-1 RNA and lower CD4+ cell counts. There was no difference in the adjusted hazards of virological failure [efavirenz versus lopinavir/ritonavir hazard ratio (HR) = 0.93, 95% confidence interval (CI): 0.77-1.12, P = 0.43], CD4 recovery (HR = 1.11, 95% CI: 0.95-1.30, P = 0.19) and clinical progression (HR = 0.71, 95% CI: 0.39-1.31, P = 0.27). There was an increased risk of discontinuation for any reason or for toxicity for lopinavir/ritonavir (HR = 2.10, 95% CI: 1.40-3.15, P = 0.0003). CD4 recovery with both drugs was also similar in the lowest CD4 strata. A higher risk of early hypertriglyceridaemia was associated with lopinavir/ritonavir-based regimens. CONCLUSIONS: Our study suggests similar virological efficacy for efavirenz- or lopinavir/ritonavir-based first-line antiretroviral regimens, but an increased risk of discontinuation because of toxicity in case of lopinavir/ritonavir-based therapy. Immunological outcome appeared similar with both regimens.

24 Article Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. 2019

Fernández-Armenteros, J M / Gómez-Arbonés, X / Buti-Soler, M / Betriu-Bars, A / Sanmartin-Novell, V / Ortega-Bravo, M / Martínez-Alonso, M / Garí, E / Portero-Otín, M / Santamaria-Babi, L / Casanova-Seuma, J M. ·Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain. · Dermatology Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain. · Department of Medicine, Faculty of Medicine, University of Lleida, Lleida, Spain. · Unitat de Suport a la Recerca Lleida, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain. · Institut Català de la Salut, Lleida, Spain. · Nephrology Department, Unitat de Detecció i Tractament de les malalties aterotrombòtiques (UDETMA), Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain. · CAP Cappont, Lleida, Spain. · Translational Immunology, University of Barcelona, Barcelona, Spain. ·J Eur Acad Dermatol Venereol · Pubmed #29953676.

ABSTRACT: BACKGROUND: Psoriasis is a very prevalent systemic chronic inflammatory disease. Major cardiovascular events are the main cause of mortality in these patients which suggests an association between psoriasis and traditional cardiovascular risk factors. OBJECTIVE: To identify classic cardiovascular risk factors and metabolic syndrome (MS) in patients with psoriasis, their possible association with its severity and compare it with the non-psoriatic population. METHODS: This is an observational and cross-sectional population study in Lleida (Spain) from a joint hospital/primary care database. RESULTS: The database comprised 398 701 individuals. There were 6868 cases registered as psoriasis (1.7%), and 499 of them (7.3%) were classified as moderate-severe psoriasis. Patients with psoriasis had a higher prevalence of traditional cardiovascular risk factors than non-psoriatic population: diabetes mellitus 2 (13.9% vs 7.4%, OR 2.01), dyslipidaemia (28.8% vs 17.4%, OR 1.92), arterial hypertension (31.2% vs 19.0%, OR 1.93), obesity (33.7% vs 28.1%, OR 1.30), altered fasting basal glycaemia (21.4% vs 15.1%, OR 1.54), low cholesterol HDL (38.1% vs 32.3%, OR 1.29), hypertriglyceridaemia (45.7% vs 35.2%, OR 1.55) and high waist circumference (75.7% vs 72.3%, OR 1.19). MS was more prevalent in psoriatic patients (28.3% vs 15.1%, OR 2.21), and cardiovascular risk factors were similar between psoriasis severity groups. Psoriatic patients had a higher prevalence of ischaemic heart disease (3.3% vs 1.8%, OR 1.87) and vascular cerebral accidents (1.8% vs 1.2%, OR 1.55). A model for MS showed a significant nonlinear relationship with age and sex and significant differences between patients with and without psoriasis. CONCLUSION: We found statistically significant differences in relation to the prevalence of cardiovascular risk factors, MS and major cardiovascular events in psoriatic patients. However, differences were not seen between psoriasis severity groups. Our work reinforces the need for a multidisciplinary approach and close monitoring of cardiovascular risk factors in these patients to prevent a cardiovascular event.

25 Article Potential Involvement of Peripheral Leptin/STAT3 Signaling in the Effects of Resveratrol and Its Metabolites on Reducing Body Fat Accumulation. 2018

Ardid-Ruiz, Andrea / Ibars, Maria / Mena, Pedro / Del Rio, Daniele / Muguerza, Begoña / Bladé, Cinta / Arola, Lluís / Aragonès, Gerard / Suárez, Manuel. ·Department of Biochemistry and Biotechnology, Nutrigenomics Research Group, Universitat Rovira i Virgili, 43007 Tarragona, Spain. andrea.ardid@urv.cat. · Department of Biochemistry and Biotechnology, Nutrigenomics Research Group, Universitat Rovira i Virgili, 43007 Tarragona, Spain. maria.ibars@urv.cat. · Department of Food and Drugs, Human Nutrition Unit, University of Parma, 43125 Parma, Italy. pedromiguel.menaparreno@unipr.it. · Department of Veterinary Medicine, University of Parma, 43125 Parma, Italy. daniele.delrio@unipr.it. · School for Advanced Studies on Food and Nutrition, University of Parma, 43125 Parma, Italy. daniele.delrio@unipr.it. · Microbiome Research Hub, University of Parma, 43125 Parma, Italy. daniele.delrio@unipr.it. · Department of Biochemistry and Biotechnology, Nutrigenomics Research Group, Universitat Rovira i Virgili, 43007 Tarragona, Spain. begona.muguerza@urv.cat. · Eurecat, Centre Tecnològic de Catalunya, Unit of Nutrition and Health, 43204 Reus, Spain. begona.muguerza@urv.cat. · Department of Biochemistry and Biotechnology, Nutrigenomics Research Group, Universitat Rovira i Virgili, 43007 Tarragona, Spain. mariacinta.blade@urv.cat. · Department of Biochemistry and Biotechnology, Nutrigenomics Research Group, Universitat Rovira i Virgili, 43007 Tarragona, Spain. lluis.arola@urv.cat. · Eurecat, Centre Tecnològic de Catalunya, Unit of Nutrition and Health, 43204 Reus, Spain. lluis.arola@urv.cat. · Department of Biochemistry and Biotechnology, Nutrigenomics Research Group, Universitat Rovira i Virgili, 43007 Tarragona, Spain. gerard.aragones@urv.cat. · Department of Biochemistry and Biotechnology, Nutrigenomics Research Group, Universitat Rovira i Virgili, 43007 Tarragona, Spain. manuel.suarez@urv.cat. ·Nutrients · Pubmed #30441779.

ABSTRACT: Bioactive compounds such as polyphenols have increased in importance in recent years, and among them, resveratrol (3,5,4'-trihydroxy-trans-stilbene) has generated great interest as an anti-obesity agent. Recent investigations have highlighted the importance of leptin signaling in lipid metabolism in peripheral organs. The aims of this study were (1) to investigate whether resveratrol can reduce fat accumulation in peripheral tissues by increasing their leptin sensitivity and (2) to identify which resveratrol-derived circulating metabolites are potentially involved in these metabolic effects. Serum leptin levels and the leptin signaling pathway were assessed in diet-induced obese rats. Moreover, serum metabolites of resveratrol were studied by ultra-high performance liquid chromatography⁻mass spectrometry (UHPLC-MS